As a cornerstone of cancer immunotherapy, ICB reactivates the anti-tumor immune function of T cells by blocking immune checkpoint molecules such as PD-1/PD-L1, and has emerged as a landmark breakthrough in cancer immunotherapy. Here, PDCD1 is linked to neoplasm.